US Supreme Court narrows inducement liability for 'skinny label' generic drugs
The Supreme Court unanimously ruled Thursday that generic drug manufacturer Hikma Pharmaceuticals' FDA-approved skinny label and marketing materials describing its product as equivalent to Amarin Pharma's branded drug were insufficient to...To view the full article, register now.
Already a subscriber? Click here to view full article